The Latest in CLL

FDA approves pirtobrutinib for previously treated CLL/SLL

December 4, 2023

‘Promising’ new txs for most common adult leukemia

September 8, 2023

CLL combo treatment: Phase-3 study inconclusive

July 3, 2023

CLL: Venetoclax-obinutuzumab combo effective long term

June 16, 2023

Ibrutinib + venetoclax: High-risk features don’t lessen CLL response

June 15, 2023

CLL

`Remarkable’: CAR T therapy for CLL/SLL

June 8, 2023

New CLL meds: Improved survival rates, 1990-2018

June 5, 2023

CLL

Venetoclax boosts ibrutinib in high-risk CLL

May 22, 2023

CLL

CLL: Venetoclax combos top first-line chemoimmunotherapy

May 12, 2023

CLL: Black patients die sooner than Whites

May 8, 2023

Frontline CLL treatment: Avoiding adverse events

April 24, 2023

CLL

Price of CLL Rx rises, despite competition

April 12, 2023

CLL

MRD: Powerful metric for CLL research

April 5, 2023

CLL

B-cell cancers: Sparse insight into preventing infections

March 28, 2023

CLL and surgery are more compatible than ever

March 20, 2023